On March 6th, 2024, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published research co-authored by 2019 AFAR Grantee Dibyadeep Datta, PhD, on the newly discovered blood biomarker indicating early-stage Alzheimer’s disease. Identifying these early signs, such as blood biomarkers, could one day help guide treatments that could prevent Alzheimer's disease.
The abstract states:
“Tau phosphorylated at threonine-217 (pT217-tau) is a novel fluid-based biomarker that predicts onset of Alzheimer's disease (AD) symptoms, but little is known about how pT217-tau arises in the brain, as soluble pT217-tau is dephosphorylated post mortem in humans...These data help to explain why pT217-tau predicts degeneration in AD and how it gains access to CSF and plasma to serve as a fluid biomarker.”
This research was advanced in part thanks to The Irene Diamond Fund/AFAR Postdoctoral Transition Awards in Aging that Dr. Datta received in 2019.
Read the article, “Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration” here.
For more, read a relate press release here.
